Company BioPorto A/S

Equities

BIOPOR

DK0011048619

Medical Equipment, Supplies & Distribution

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per Business

Sales per region

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Diagnostic & Testing Substances

Market Closed - Nasdaq Copenhagen Other stock markets 10:53:03 2024-04-23 am EDT			5-day change	1st Jan Change
1.23 ^DKK	+0.65%		-2.84%	-41.15%

Apr. 10	BioPorto Names New Chief Legal Officer	MT
Apr. 10	Bioporto A/S Appoints Gry Louise Husby Larsen as Chief Legal Officer and Member of the Executive Management Team, Effective as of April 15, 2024	CI

Bioporto A/S is a Denmark-based company engaged in the development and marketing of in vitro diagnostic (IVD) assays. The Companyâs portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.

Number of employees: 29

DKK in Million	2022	Weight	2023	Weight	Delta
Neutrophil Gelatinase-associated Lipocalin Tests 59.9 %	15	51.3 %	19	59.9 %	+24.91%
Antibodies 34.5 %	12	41.5 %	11	34.5 %	-11.24%
Enzyme-linked Immunosorbent Assay Kits 5.4 %	2	6.3 %	2	5.4 %	-8.82%
Royalty and Other 0.1 %	0	0.8 %	0	0.1 %	-81.48%

DKK in Million	2022	Weight	2023	Weight	Delta
United States 55.9 %	-	-	17	55.9 %	-
Europe 31.3 %	10	34.8 %	10	31.3 %	-3.82%
Asia 12.2 %	4	13.5 %	4	12.2 %	-3.70%
North America 0.6 %	15	51.6 %	0	0.6 %	-98.80%

Managers	Title	Age	Since
Peter Morch Eriksen CEO	Chief Executive Officer	64	13-07-17
Ursula Klause CTO	Chief Tech/Sci/R&D Officer	-	20-11-30
Prasad Devarajan CTO	Chief Tech/Sci/R&D Officer	-	22-06-30
Jan Kuhlmann Andersen COO	Chief Operating Officer	63	15-10-03
Jennifer Zonderman SAM	Sales & Marketing	-	19-04-30

Members of the board	Title	Age	Since
John McDonough CHM	Chairman	65	21-04-28
Donnie Hardison BRD	Director/Board Member	74	21-04-28
Peter Morch Eriksen CEO	Chief Executive Officer	64	13-07-17
Michael Singer BRD	Director/Board Member	51	19-08-14
Jan Kuhlmann Andersen COO	Chief Operating Officer	63	15-10-03

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	379,670,461	338,546,015 ( 89.17 %)	13,000 ( 0.003424 %)	89.17 %

Name	Equities	%	Valuation
Jan Leth Christensen 10.59 %	40,212,165	10.59 %	8 M kr
Media-Invest Danmark A/S 7.366 %	27,967,206	7.366 %	5 M kr
Danske Bank A/S (Investment Management) 0.1648 %	625,553	0.1648 %	118 699 kr
Chris Lindop 0.1470 %	558,108	0.1470 %	105 901 kr
Mandarine Gestion SA 0.0746 %	283,326	0.0746 %	53 761 kr
Michael Singer 0.0551 %	209,291	0.0551 %	39 713 kr
Peter Morch Eriksen 0.0347 %	131,882	0.0347 %	25 025 kr
Dimensional Fund Advisors Ltd. 0.0291 %	110,656	0.0291 %	20 997 kr
Sydbank A/S (Investment Management) 0.0127 %	48,076	0.0127 %	9 122 kr
BIOPORTO A/S 0.003424 %	13,000	0.003424 %	2 467 kr

Name	Equities	%	Valuation
BIOPORTO A/S 0.00%	13,000	0.00%	2,467 $

Bioporto A/S

Tuborg Havnevej 15 Ground Floor

2900, Hellerup

+45 45 29 00 00

http://www.bioporto.com

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.23 DKK

Average target price

5 DKK

Spread / Average Target

+306.50%

Consensus

Estimates Revisions

Company calendar

Healthcare

Healthcare Services

Healthcare Equipment & Supplies

Medical Equipment, Supplies & Distribution

Diagnostic & Testing Substances

	1st Jan change	Capi.
BIOPORTO A/S	-41.15%	66.19M
BIOMÉRIEUX	+0.80%	12.66B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-12.75%	7.04B
DIASORIN S.P.A.	+2.81%	5.39B
AUTOBIO DIAGNOSTICS CO., LTD.	-1.37%	4.45B
LANTHEUS HOLDINGS, INC.	+3.89%	4.32B
10X GENOMICS, INC.	-50.71%	3.31B
ANDON HEALTH CO., LTD.	+9.29%	2.6B
VITROLIFE AB	-15.10%	2.01B
MYRIAD GENETICS, INC.	-2.82%	1.67B

Diagnostic & Testing Substances